参考文献:1.Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287–9.PubMed CrossRef 2.Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–53.PubMed CrossRef 3.Lerut T, Decker G, Coosemans W, De Leyn P, Decaluwe H, Nafteux P, et al. Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction. Recent Results Cancer Res. 2010;182:127–42.PubMed CrossRef 4.Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 2001;30:1415–25.PubMed CrossRef 5.Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2–9.PubMed CrossRef 6.Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21:322–7.PubMed CrossRef 7.Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery. 2008;143:499–508.PubMed CrossRef 8.Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–9.PubMed CrossRef 9.Stein HJ, Feith M, Siewert JR. Cancer of the esophagogastric junction. Surg Oncol. 2000;9:35–41.PubMed CrossRef 10.Sobin LH, Compton CC. TNM seventh edition: what’s new, what’s changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 2010;116:5336–9.PubMed CrossRef 11.Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef 12.Association JGC. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRef 13.Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.PubMed CrossRef 14.Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254:274–80.PubMed CrossRef 15.Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100:261–6.PubMed CrossRef 16.Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer. 2013;16:301–8.PubMed CrossRef 17.Goto H, Tokunaga M, Sugisawa N, Tanizawa Y, Bando E, Kawamura T, et al. Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer. 2013;16:590–5.PubMed CrossRef 18.Hasegawa S, Yoshikawa T, Rino Y, Oshima T, Aoyama T, Hayashi T, et al. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol. 2013;20:4252–9.PubMed CrossRef 19.Yabusaki H, Nashimoto A, Matsuki A, Aizawa M. Comparison of the surgical treatment strategies for Siewert type II squamous cell carcinoma in the same area as esophagogastric junction carcinoma: data from a single Japanese high-volume cancer center. Surg Today. 2014;44:1522–8.PubMed PubMedCentral CrossRef 20.Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, et al. Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today. 2012;42:351–8.PubMed CrossRef 21.Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.PubMed CrossRef
作者单位:Takaki Yoshikawa (1) Hiroya Takeuchi (2) Shinichi Hasegawa (1) Isao Nozaki (3) Kentaro Kishi (4) Seiji Ito (5) Masaki Ohi (6) Shinji Mine (7) Johji Hara (8) Tatsuo Matsuda (2) Naoki Hiki (7) Yukinori Kurokawa (8)
1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan 2. Department of Surgery, Keio University School of Medicine, Tokyo, Japan 3. Department of Surgery, Shikoku Cancer Center, Matsuyama, Japan 4. Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan 5. Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan 6. Department of Innovative Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan 7. Department of Surgery, Cancer Institute Ariake Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan 8. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2, E2, Yamadaoka, Suita, Osaka, 565-0871, Japan
刊物类别:Medicine
刊物主题:Medicine & Public Health Oncology Gastroenterology Surgical Oncology Pathology Radiotherapy
出版者:Springer Japan
ISSN:1436-3305
文摘
Backgrounds The aim of this study was to evaluate the theoretical therapeutic impact of dissecting each lymph node station for adenocarcinoma and squamous cell carcinoma of the esophagogastric junction.